securities fraud

Apollo Global Management faces securities fraud class action over undisclosed Epstein communications. Stock fell 16% during class period; investors can file claims by May 1, 2026.

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud tied to FDA rejection of relacorilant, triggering 50% stock plunge.

Ultragenyx ($RARE) faces class action lawsuit over failed setrusumab Phase 3 trials, with stock down 42%. Investors have until April 6, 2026 to seek lead plaintiff status.

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

Class action lawsuit filed against Gemini Space Station for alleged IPO misstatements regarding crypto platform viability and international expansion. Application deadline: May 18, 2026.

Class action lawsuit filed against $ENPH alleges securities fraud over channel inventory management and Clean Energy Credit disclosure failures. Deadline for lead plaintiff claims: April 20, 2026.

Schall Law Firm seeks investors in $ALIT securities fraud class action, alleging false statements about operations, dividends, and expenses.

Schall Law Firm seeks Camping World Holdings investors in securities fraud class action over alleged false inventory management and demand statements.

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Pomerantz LLP investigates Banco Santander for potential securities fraud over undisclosed UK lender collapse, with stock falling 7.57% over two trading sessions.

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

BlackRock faces securities fraud investigation after implementing 5% quarterly redemption caps on HPS Corporate Lending Fund, triggering 7.69% stock decline.

Pomerantz Law Firm investigates potential securities fraud at Babcock & Wilcox following allegations linking a major power contract to its largest shareholder.

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

Pomerantz LLP investigates Freshpet for potential securities fraud tied to unsupported 'human grade' pet food claims, triggering sharp stock decline.